Kavar Capital Partners Group LLC Has $972,000 Stock Holdings in GSK plc (NYSE:GSK)

Kavar Capital Partners Group LLC reduced its holdings in shares of GSK plc (NYSE:GSK) by 11.5% during the 4th quarter, Holdings Channel.com reports. The fund owned 28,730 shares of the pharmaceutical company’s stock after selling 3,742 shares during the period. Kavar Capital Partners Group LLC’s holdings in GSK were worth $972,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Blue Trust Inc. raised its stake in GSK by 16.7% during the fourth quarter. Blue Trust Inc. now owns 12,505 shares of the pharmaceutical company’s stock worth $423,000 after acquiring an additional 1,785 shares in the last quarter. Grimes & Company Inc. acquired a new stake in shares of GSK during the 4th quarter worth about $4,731,000. Geneos Wealth Management Inc. bought a new position in GSK during the 4th quarter valued at about $145,000. Brighton Jones LLC acquired a new position in GSK in the fourth quarter valued at about $528,000. Finally, Kelleher Financial Advisors grew its stake in GSK by 13.5% during the fourth quarter. Kelleher Financial Advisors now owns 11,387 shares of the pharmaceutical company’s stock worth $385,000 after buying an additional 1,357 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. StockNews.com lowered GSK from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 21st. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Finally, Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and cut their price target for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Six analysts have rated the stock with a hold rating, one has given a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Stock Performance

Shares of GSK stock opened at $34.29 on Monday. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.92. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. The stock has a market capitalization of $71.06 billion, a price-to-earnings ratio of 22.26, a PEG ratio of 1.31 and a beta of 0.63. The firm has a fifty day moving average of $33.91 and a two-hundred day moving average of $37.80.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were given a dividend of $0.3928 per share. This is a positive change from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a dividend yield of 4.58%. The ex-dividend date of this dividend was Friday, November 15th. GSK’s payout ratio is presently 96.10%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.